YOU ARE ABOUT TO EXIT A US HEMANEXT CORPORATE WEBSITE FOR A GLOBAL HEMANEXT ONE PRODUCT WEBSITE
Please be aware that the website you have requested is intended for the residents of countries in the European Union. The site may contain information on products or uses of those products that are not cleared, approved, or otherwise authorized in all countries or regions, including the US Food & Drug Administration.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
Hemanext to Present New Red Blood Cell Research Data at AABB 2020 Four abstracts add to the growing body of evidence supporting hypoxic storage of RBCs LEXINGTON, Mass., September 29, 2020 Hemanext Inc., a privately held medical technology company dedicated to...
Celebrating David Herman (1946 – 2020) With deep sadness, we record the untimely death in London on June 3rd of our fellow Board Director, investor and friend, David Herman. David served Hemanext as a member of the board for 10 years. He brought to this role a...
Join Us June 19th! Help Shine the Light on Sickle Cell Disease On June 19th, people around the globe will come together to recognize the United Nation’s World Sickle Cell Awareness Day through a wide variety of online activities. The celebration is called Shine the...
Thalassaemia International Federation and Hemanext® Inc. Announce New Strategic Alliance Organizations create partnership to support the needs of people living with hemoglobin disorders NICOSIA, Cyprus and LEXINGTON, Mass., June 10, 2020 The Thalassaemia International...
Sickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic Partnership New alliance designed to enhance the lives of people living with sickle cell disease HANOVER, Md. and LEXINGTON, Mass., May 6, 2020 Sickle Cell Disease Association of...
PURPOSE Hemanext is committed to conducting honest, truthful, and reverent research activities, which are consistent with its Mission Statement. Hemanext assures objectivity of its research by maintaining that its Public Health Service (“PHS”), including the National...
Hemanext Announces CE Mark Submission for the HEMANEXT ONE Red Blood Cell Processing System Regulatory filing is a major step toward commercialization of transfusion-medicine innovation LEXINGTON, Mass., November 1, 2019 Hemanext Inc., a privately held medical...
Hemanext to Present Extensive, Significant Red Blood Cell Data at AABB 2019 AABB accepted all eight research abstracts for presentation at annual conference October 3, 2019 Hemanext, a privately held medical technology company dedicated to creating a world with fewer...
Hemanext will be exhibiting at the upcoming Remote Damage Control Resuscitation (RDCR) Symposium, taking place June 23 – 26, 2019 in Osøyro, Norway. The RDCR Symposium is organized by THOR – The Hemostasis and Oxygen Research Network. THOR is an international...
